A Phase III/IV, Single Arm, Multicenter Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (TAIL)

Status: Active, no longer recruiting

Phase of Trial: Phase III/IV

Latest Information Update: 27 Nov 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions
Acronyms TAIL
Sponsors Roche

Most Recent Events

23 Oct 2019 Planned End Date changed from 31 Aug 2021 to 29 Apr 2021.
23 Oct 2019 Planned primary completion date changed from 31 Aug 2019 to 29 Apr 2021.
12 Aug 2019 Status changed from recruiting to active, no longer recruiting.

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Welcome to AdisInsight